Detección de anticuerpos antiestreptococos, anti-enolasa y antineurales en sujetos con trastornos psiquiátricos de inicio temprano / Detection of anti-streptococcal, anti-enolase, and anti-neural antibodies in subjects with earlyonset psychiatric disorders

Introducción. La infección por Estreptococo del grupo A puede ocasionar secuelas post-infecciosas entre las que se han reportado un espectro de trastornos obsesivos-compulsivos y tics de aparición en la edad pediátrica y origen autoinmune (PANDAS). No ha sido diseñada una prueba inmunológica que permita diagnosticar inequívocamente estos trastornos. En este trabajo se evaluó la detección en suero de anticuerpos contra Enolasa cerebral humana (AE), tejido neural (AN) y Estreptococo (AS) como herramienta de laboratorio para el diagnóstico de trastornos psiquiátricos de inicio temprano. Metodología. Los anticuerpos séricos contra Enolasa cerebral humana, proteínas totales del Estreptococo y proteínas totales cerebrales fueron detectados mediante la metodología de ELISA en 37 individuos con diagnóstico presuntivo de PANDAS y en 12 sujetos sanos de México y Cuba. Resultados. Los títulos de anticuerpos contra AE y AS fueron más elevados en el grupo de pacientes vs controles (t-student, tAE=-2.17, P=0.035; tAS=-2.68, P=0.01, n=12 y 37/grupo, gl=47, nivel de significación de 0.05), mientras que los títulos de anticuerpos AN no difirieron entre ambos grupos (P(t)=0.05). La seropositividad (títulos > mediacontrol + IC95) simultánea a los tres anticuerpos fue mayor (51.4 %) en los individuos del grupo de los pacientes comparado con los controles (8.3%) (X2 =5.27, P=0.022, gl=1, n=49). Conclusiones. La detección simultánea de los tres anticuerpos séricos podría brindar información útil para el diagnóstico etiológico de los individuos con trastorno obsesivo compulsivo de inicio temprano asociados con la infección por Estreptococo y en consecuencia para indicar una terapéutica adecuada

Introduction. Infection with group A Streptococcus (Strep A) can cause post-infectious sequelae, including a spectrum of childhood-onset obsessive-compulsive (OCD) and tic disorders with autoimmune origin (PANDAS, Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections). Until now, no single immunological test has been designed that unequivocally diagnoses these disorders. In this study, we assessed the detection of serum antibodies against human brain enolase (AE), neural tissue (AN) and Streptococcus (AS) as a laboratory tool for the diagnosis of early-onset psychiatric disorders. Methodology. Serum antibodies against human brain enolase, total brain proteins, and total proteins from StrepA were detected by ELISA in 37 patients with a presumptive diagnosis of PANDAS and in 12 healthy subjects from Mexico and Cuba. Results. The antibody titers against human brain enolase (AE) and Streptococcal proteins (AS) were higher in patients than in control subjects (t-student, tAE=-2.17, P=0.035; tAS=-2.68, P=0.01, n=12 and 37/group, df=47, significance level 0.05), while the neural antibody titers did not differ between the two groups (P(t)=0.05). The number of subjects (titers> mean control + CI95) with simultaneous seropositivity to all three antibodies was higher in the patient group (51.4%) than in the control group (8.3%) group (X2 =5.27, P=0.022, df=1, n=49). Conclusions. The simultaneous detection of all three of these antibodies could provide valuable information for the etiologic diagnosis of individuals with early-onset obsessive compulsive disorders associated with streptococcal infection and, consequently, for prescribing suitable therapy

Detection of anti-streptococcal, antienolase, and anti-neural antibodies in subjects with early-onset psychiatric disorders.

INTRODUCTION: Infection with group A Streptococcus (StrepA) can cause post-infectious sequelae, including a spectrum of childhood-onset obsessive-compulsive (OCD) and tic disorders with autoimmune origin (PANDAS, Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections). Until now, no single immunological test has been designed that unequivocally diagnoses these disorders. In this study, we assessed the detection of serum antibodies against human brain enolase (AE), neural tissue (AN) and Streptococcus (AS) as a laboratory tool for the diagnosis of early-onset psychiatric disorders. METHODOLOGY: Serum antibodies against human brain enolase, total brain proteins, and total proteins from StrepA were detected by ELISA in 37 patients with a presumptive diagnosis of PANDAS and in 12 healthy subjects from Mexico and Cuba. RESULTS: The antibody titers against human brain enolase (AE) and Streptococcal proteins (AS) were higher in patients than in control subjects (t-student, tAE=-2.17, P=0.035; tAS=-2.68, P=0.01, n=12 and 37/group, df=47, significance level 0.05), while the neural antibody titers did not differ between the two groups (P(t)=0.05). The number of subjects (titers> meancontrol + CI95) with simultaneous seropositivity to all three antibodies was higher in the patient group (51.4%) than in the control group (8.3%) group (X2=5.27, P=0.022, df=1, n=49). CONCLUSIONS: The simultaneous detection of all three of these antibodies could provide valuable information for the etiologic diagnosis of individuals with early-onset obsessive-compulsive disorders associated with streptococcal infection and, consequently, for prescribing suitable therapy.

Mifepristone 2.5 mg versus 5 mg daily in the treatment of leiomyoma before surgery.

OBJECTIVES: To evaluate the efficacy and safety of 2.5 mg and 5 mg mifepristone during 3 months for the treatment of uterine fibroids before surgery. DESIGN: Multicenter randomized clinical trial. LOCATIONS: Eusebio Hernández Hospital, Havana, Cuba and the Alemán Hospital, Managua, Nicaragua. SUBJECTS: Included in the study were 146 women with symptomatic uterine fibroids. TREATMENT: GROUP I: half a tablet of 5 mg (2.5 mg) mifepristone taken orally every 24 hours, and Group II: one tablet of 5 mg mifepristone taken orally every 24 hours over a period of 3 months in both groups. Two endometrial biopsies were performed. VARIABLES TO EVALUATE EFFICACY: Increase in average hemoglobin, changes in fibroid and uterine volume, and symptomatic improvement. RESULTS: The average hemoglobin at the end of treatment was 0.6 g/dL greater in the 5 mg mifepristone group (P = 0.033). In both groups there were similar reductions in fibroid volumes. Clinical improvement was more significant in the 5 mg group. CONCLUSION: The dose to be used should be 5 mg.

Expression in fibroblasts and in live animals of Entamoeba histolytica polypeptides EhCP112 and EhADH112.

EhCPADH is an immunogenic, heterodimeric protein that is formed by EhCP112 (cysteine protease) and EhADH112 (adhesin), polypeptides involved in Entamoeba histolytica's cytopathic effect, target-cell adherence and phagocytosis. The EhCPADH complex is located in the plasma membrane and cytoplasmic vacuoles. Here, the independent expression of EhCP112 and EhADH112 in fibroblasts and hamsters was analysed. Also investigated was the immunological response in animals independently inoculated with plasmid pcDNA-Ehcp112, which carries the complete cysteine protease-encoding gene, or with plasmid pcDNA-Ehadh112, which carries the C terminus of the adhesin-encoding gene, or with a mixture of both. Both proteins were expressed in the plasma membranes of the transfected fibroblasts. EhCP112 was toxic for the mammalian cells. Proteins were also independently expressed in hamsters after inoculation with the plasmids. Their expression was indirectly evaluated by the presence of antibodies in the inoculated animals. Remarkably, co-immunization of the animals with the two DNA plasmids resulted in an earlier and higher anti-E. histolytica IgG induction than immunization with separate plasmids. In contrast, the cellular immune response was not noticeably improved by the plasmid mixture. Interestingly, protection against liver abscesses was detected only in animals that received the plasmid mixture and no protection was observed in hamsters independently inoculated with plasmid pcDNA-Ehcp112 or pcDNA-Ehadh112.